APEX1 and Thrombocytopenia: Unlike PTX, which induced severe anemia and thrombocytopenia, the rhAPE1/Ref-1 and ASA combination therapy did not exhibit significant hematological toxicity, suggesting potential safety and tolerability advantages of the combination therapy over conventional chemotherapy agents like PTX.